Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 16, 2025
Daily News
June 16, 2025
- FPMAJ Calls for Expanded Range of Selection for Comparator Drugs
June 16, 2025
- PMP Drugs Should Be Excluded from Price Revisions: FPMAJ Committee Chief
June 16, 2025
- Mitsubishi’s BRD4 Degrader Now in US PI/II for Solid Tumors
June 16, 2025
- JPMA Ready to Engage with Government on CEA Debates: Statement
June 16, 2025
- Sumitomo’s Myelofibrosis Drug Earns Fast-Track Tag in US
June 16, 2025
- Japan OKs Honebuto Paper with Softened Phrasing on CEA, Sign of Change to Social Security Budgeting
June 16, 2025
- Novartis Makes Full Foray into Nephrology Space with Fabhalta: Exec
June 16, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…